Supreme Court Rules Narrowly Against Medicare Payments Cuts To 340B Hospitals

The decision doesn’t directly impact manufacturers or the 340B discounts they are required to provide – and does not address the potentially much broader regulatory issue of whether the Supreme Court’s so-called Chevron doctrine should be changed.

Manufacturer Restrictions On Discounts Being Debated In Lower Courts • Source: Shutterstock

The US Supreme Court concluded the Health and Human Services Department misconstrued the law in reducing Medicare payments for drugs purchased by hospitals using the 340B drug discount program, but did not venture into broader questions around court deference to agency interpretation of the law, in a unanimous ruling issued on 15 June.

The decision is a victory for hospitals and a setback for HHS. However, it doesn’t directly impact manufacturers or the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet